Delving into the Latest Updates on IDL-2965 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

αvβ1 inhibitors(Integrin alpha-V/beta-1 inhibitors), αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ6 antagonists(Integrin alpha-V/beta-6 antagonists)

Therapeutic Areas

Digestive System DisordersRespiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary FibrosisNonalcoholic Steatohepatitis

Inactive Indication-

Originator Organization

Indalo Therapeutics, Inc.

Active Organization

Indalo Therapeutics, Inc.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Volumetric muscle loss (VML) causes irrecoverable loss of muscle mass and strength and results in permanent disability. VML injury shows extensive fibrosis, which impedes functional tissue regeneration. Our lab has created a biosponge scaffold composed of extracellular matrix (ECM) proteins (i.e., biosponge) that can enhance muscle regeneration and function following VML. In this work, a potent small molecule inhibitor of alpha v-subunit containing integrins known as IDL-2965 was incorporated into the biosponges for localized suppression of fibrosis post-VML. Our results demonstrate that local delivery of IDL-2965 via the biosponges attenuated the deposition of fibrotic tissue preceded by a downregulation of profibrotic genes in VML-injured muscles. The reduction in fibrotic tissue had no detrimental effects on muscle mass, function, size, or vascularity. Overall, these findings suggest that the codelivery of biosponges and IDL-2965 is a safe and effective strategy for the mitigation of fibrotic tissue deposition in VML-injured muscles.

100 Deals associated with IDL-2965

Login to view more data